Bookmark and Share

Petr F Hausner M.D., Ph.D.

Academic Title: Associate Professor
Primary Appointment: Medicine
phausner@umm.edu
Location: UMMC, Room S9D15
Phone: (410) 328-2567
Fax: (410) 328-6896

Research Interests:

Major clinical interests center on the management of patients with solid cancers in particular mesothelioma and other thoracic malignancies including lung cancer as well as melanoma and other skin cancers including Kaposi sarcoma. To advance the management of these cancers and offer patients with these cancers optimal care, I perform clinical trials for these diseases. 

As an IRB vice-chair I appreciate and contribute to the optimization of the mechanisms of clinical trials. Bias in clinical trials and its reduction by statistical methods is of great interest to me as is optimization of clinical research. As Chief of Hematology and Oncology at the Baltimore VA, I am interested in the administration of oncology departments and in improving the safety of patients while preserving effectiveness of cancer care.

Laboratory research is centered on the cellular and tissue level of cancer growth. I study gap junctional intercellular communications, and their function in drug resistance.  Phenotypic changes related to the epithelial mesothelial transition are studied in melanoma and mesothelioma. The milky spots of the pleural and peritoneal cavities are studied to better understand the pathogenesis and spread of mesothelioma. Tumor stem cells as the ultimate object of cancer therapy will be studied.


Publications:

Hausner P, Venzon DJ, Grogan W, Kirsch I:  The "Comparative Growth Assay“: Examining the Interplay of Anti-cancer Agents with Cells Carrying Single Gene Alterations.  Neoplasia, 1(4):356-67, 1999.

Kwong KF, Edelman MJ, Suntharalingam M, Cooper LB, Gamliel Z, Burrows W, Hausner P, Doyle LA, Krasna MJ.  High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg, 129(6):1250-7, 2005.

Edelman, MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M, Bisaccia S: Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell-lung cancer. J Clin Oncol, 23(24):5774-8, 2005.

Tummala, MK, Hausner, PF., McGuire, WP, Gipson, T, Berkman A: Testis: A sanctuary site in Merkel cell carcinoma. J Clin Oncol, 24(6):1008-9, 2006.

Gormley N, Edelman MJ.,Smith R., Hausner P, Bedor M., Bisaccia S. Phase II trial of docetaxel and topotecan in recurrent and extensive stage small cell lung cancer in press.

Kwong, KF, Edelman, MJ, Sutharaligman, M, Gamliel, Z, Burrows, W, Bisaccia, SP, Cooper, LB, Kennedy, NL, Hausner, P, Doyle, LA, Krasna, MJ.: Surgical results of a phase II study of neoadjuvant hyperfractionated radiotherapy with concurrent chemotherapy followed by surgery in stage III non-small cell lung cancer in press.

Hassan, R, Alexander, R. Antman, K, Boffetta, P, Churg,A, Coit, D, Hausner, P, Kennedy, R, Kindler, H, Metintas, M, Mutti, L, Onda, M., Pass, H, Premkumar, A, Toggli, V, Sterman, D., Sugarbaker, P, Taub, R, Verschraegen.: Current Treatment Options and Biology of Peritoneal Mesothelioma: Meeting Summary of the First NIH Peritoneal Mesothelioma  Conference,  Annals of Oncology, 2006,  in press

Gamliel Z, Burrows WM, Sonett JR, Suntharalingam M, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Kwong KF, Krasna MJ: Pneumonectomy for Lung Cancer Can be Performed Safely Following Preoperative Concurrent Chemotherapy and High-Dose Radiation  (Presented at the Forty-second Annual Meeting of the Society of Thoracic Surgeons, Chicago, Illinois, January 31, 2006.  Control number: 326. )